COSCIENS Biopharma Inc
TSX:CSCI
COSCIENS Biopharma Inc
TSX:CSCI
Price:
2.94
CAD
4.63%
Market Closed
Market Cap:
CA$9.3m
Relative Value
The Relative Value of one
CSCI
stock under the Base Case scenario is
19.64
CAD.
Compared to the current market price of 2.94 CAD,
COSCIENS Biopharma Inc
is
Undervalued by 85%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CSCI
Relative Value
Base Case
19.64
CAD
Undervaluation 85%
Multiples Across Competitors
CSCI Competitors Multiples
COSCIENS Biopharma Inc Competitors
COSCIENS Biopharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
COSCIENS Biopharma Inc
TSX:CSCI
|
9.4m CAD | 0.8 | -0.5 | -0 | -0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD | 6.5 | 164.5 | 16 | 22.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.1B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD | 6.4 | 22.8 | 15.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD | 9.9 | 31.7 | 23.2 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD | 5.6 | 18 | 15.2 | 17.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD | 3.9 | 20.2 | 13.5 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.3B EUR | 14 | 32.9 | 56 | 57.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
